Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Telo Genomics Corp (TELO.VN)

Telo Genomics Corp (TELO.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 15,285
  • Shares Outstanding, K 74,560
  • Annual Sales, $ 0 K
  • Annual Income, $ -2,821 K
  • 60-Month Beta 0.23
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 25.50
Trade TELO.VN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.05
  • Most Recent Earnings $-0.01 on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Diagnostics & Research

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.140 +32.14%
on 06/21/24
0.220 -15.91%
on 06/07/24
+0.005 (+2.78%)
since 05/24/24
3-Month
0.105 +76.19%
on 04/02/24
0.225 -17.78%
on 04/18/24
+0.070 (+60.87%)
since 03/28/24
52-Week
0.105 +76.19%
on 04/02/24
0.300 -38.33%
on 09/07/23
-0.095 (-33.93%)
since 06/27/23

Most Recent Stories

More News
Telo Genomics Announces Its TeloViewSMM Test Is Accepted as Laboratory Developed Test by CAP

Toronto, Ontario--(Newsfile Corp. - June 18, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform...

TDSGF : 0.1577 (+4.02%)
TELO.VN : 0.185 (-9.76%)
Telo Genomics Presents Proprietary Artificial Intelligence Methodologies at ASCO 2024

Toronto, Ontario--(Newsfile Corp. - June 12, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3D0A) ("Telo" or the "Company"), is pleased to announce that results of the development, validation...

TDSGF : 0.1577 (+4.02%)
TELO.VN : 0.185 (-9.76%)
Telo Genomics Announces Publication of Results from Its Smoldering Myeloma Clinical Study in the American Journal of Hematology

Toronto, Ontario--(Newsfile Corp. - May 30, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA), (the "Company" or "Telo"), a biotech company developing the industry's leading telomere...

TDSGF : 0.1577 (+4.02%)
TELO.VN : 0.185 (-9.76%)
Telo Genomics and Emery Pharma Announce Collaboration

Toronto, Ontario--(Newsfile Corp. - May 15, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform...

TDSGF : 0.1577 (+4.02%)
TELO.VN : 0.185 (-9.76%)
Telo Genomics Receives Accreditation from College of American Pathologists

Toronto, Ontario--(Newsfile Corp. - April 10, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform...

TDSGF : 0.1577 (+4.02%)
TELO.VN : 0.185 (-9.76%)
Telo Genomics' Flagship MRD Clinical Trial Expands into Multi-Center Trial

Toronto, Ontario--(Newsfile Corp. - April 2, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform...

TDSGF : 0.1577 (+4.02%)
TELO.VN : 0.185 (-9.76%)
Telo Genomics Initiates MRD Clinical Trial for Multiple Myeloma Patients

Toronto, Ontario--(Newsfile Corp. - February 13, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to announce that it has received the first patient sample for...

TDSGF : 0.1577 (+4.02%)
TELO.VN : 0.185 (-9.76%)
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030

EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NYSE:BMY),(NYSE:TMO),(NASDAQ:NTRA),(NASDAQ:NEO) EQNX::TICKER_END

TDSGF : 0.1577 (+4.02%)
TELO.VN : 0.185 (-9.76%)
BMY : 41.53 (+0.05%)
TMO : 553.00 (+0.40%)
NTRA : 108.29 (-1.56%)
NEO : 13.87 (+3.97%)
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030

TDSGF : 0.1577 (+4.02%)
TELO.VN : 0.185 (-9.76%)
BMY : 41.53 (+0.05%)
TMO : 553.00 (+0.40%)
NTRA : 108.29 (-1.56%)
NEO : 13.87 (+3.97%)
Telo Genomics Engages US Diagnostics Experts to Power Product Adoption in the US

Toronto, Ontario--(Newsfile Corp. - January 30, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to announce that it has engaged Trusted Health Advisors (THA),...

TDSGF : 0.1577 (+4.02%)
TELO.VN : 0.185 (-9.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in the development and commercialization of diagnostic and prognostic products. The company is developing diagnostic and prognostic products for cancer and neurological disorders.

See More

Key Turning Points

3rd Resistance Point 0.185
2nd Resistance Point 0.185
1st Resistance Point 0.185
Last Price 0.185
1st Support Level 0.185
2nd Support Level 0.185
3rd Support Level 0.185

See More

52-Week High 0.300
Fibonacci 61.8% 0.226
Fibonacci 50% 0.203
Last Price 0.185
Fibonacci 38.2% 0.179
52-Week Low 0.105

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar